(S)-3,3-Dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid

Catalog No. :
ACTLQD285
CAS No. :
1425038-19-2
Molecular Formula :
C15H23NO4
Molecular Weight :
281.35

IUPAC Name:(S)-3,3-Dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid

(S)-3,3-Dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-3,3-Dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid
IUPAC Name(S)-3,3-Dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid
Molecular FormulaC15H23NO4
Molecular Weight281.35
SMILESCC(C)(C)[C@H](NC(O[C@H]1[C@H](CCCC#C)C1)=O)C(O)=O
InChI KeyZLNLGHIMCOKISX-IJLUTSLNSA-N
Synonym(s)-3,3-diMethyl-2-((1r,2r)-2-pent-4-ynyl- CyclopropoxycarbonylaMino)-butyricacid;3-Methyl-N-[[[(1R,2R)-2-(4-pentyn-1-yl)cyclopropyl]oxy]carbonyl]-L-valine;(S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid;Grazoprevir int;(S)-3,3-dimethyl-2-(((1R,2R)-2-(pent-4-ynyl)cyclopropoxy)carbonylamino)butanoic acid;EOS-62311;Grazoprevir Intermediate 3;2-methylpropan-2-amine(S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoate
CAS No.1425038-19-2

Synthetic Route by SureRoute

1. ACTLQD285 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTLQD285 route product structure diagram
    ACTLQD2851425038-19-2
Inquiry

2. ACTLQD285 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTLQD285 route product structure diagram
    ACTLQD2851425038-19-2
Inquiry

Comments (0)